Edwin Kania Net Worth

The estimated Net Worth of Edwin M Jr Kania is at least $102 Million dollars as of 29 November 2021. Mr. Kania owns over 100,000 units of TransMedics stock worth over $43,559,042 and over the last 21 years he sold TMDX stock worth over $58,575,916. In addition, he makes $0 as Independent Director at TransMedics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kania TMDX stock SEC Form 4 insiders trading

Edwin has made over 8 trades of the TransMedics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of TMDX stock worth $2,256,000 on 29 November 2021.

The largest trade he's ever made was selling 1,000,000 units of TransMedics stock on 22 April 2014 worth over $32,050,000. On average, Edwin trades about 72,407 units every 90 days since 2003. As of 29 November 2021 he still owns at least 302,893 units of TransMedics stock.

You can see the complete history of Mr. Kania stock trades at the bottom of the page.

Edwin Kania biography

Edwin M. Kania Jr. serves as Independent Director of the Company. Mr. Kania is the managing partner and chairman of FarField Partners, a personal venture capital investment and advisory firm. Mr. Kania was co-founder of Flagship Ventures and served as Flagship’s Chairman between 2001 and 2014. He continues as Managing Partner for the three Flagship funds raised during that period and also continues as Managing Partner for the predecessor OneLiberty Funds that were an early lead investor in our company. During Mr. Kania’s 35 years in the venture capital industry, he has served on the boards of numerous privately and publicly held companies, including previous board positions at Acceleron Pharma and Selecta Biosciences. Mr. Kania earned his Bachelor’s degree in physics from Dartmouth College and his MBA from Harvard Business School.

How old is Edwin Kania?

Edwin Kania is 62, he's been the Independent Director of TransMedics since 2003. There are 3 older and 13 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.

What's Edwin Kania's mailing address?

Edwin's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at TransMedics

Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein, and James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.

What does TransMedics do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Complete history of Mr. Kania stock trades at Acceleron Pharma Inc, Exact Sciences, Selecta Biosciences Inc, Moderna Inc, and TransMedics

TransMedics executives and stock owners

TransMedics executives and other stock owners filed with the SEC include:

• Waleed Hassanein,
  President, Chief Executive Officer, Director
• Tamer Khayal,
  Chief Commercial Officer
• Dr. Waleed H. Hassanein,
  Founder, MD, CEO, Pres & Director
• Dr. Tamer I. Khayal,
  Chief Commercial Officer
• Stephen Gordon,
  CFO. Treasurer & Sec.
• Stephen Gordon,
  Chief Financial Officer, Treasurer, Secretary
• David Weill,
  Independent Director
• James Tobin,
  Independent Chairman of the Board
• Thomas Gunderson,
  Independent Director
• Edward Basile,
  Independent Director
• Edwin Kania,
  Independent Director
• John Sullivan,
  Vice President - Quality and Engineering
• Miriam Provost,
  Vice President - Global Regulatory Affairs
• Laura Damme,
  Vice President - Clinical Affairs
• John Carey,
  Vice President - Operations
• Susan Goodman,
  VP of HR
• Mark Anderson,
  Sr. Director of Technology Devel.
• Ike Okonkwo,
  VP of Fin. & Accounting
• John F. Carey,
  VP of Operations
• Therapeutics Corp Lung Biot...,
  
• Ventures Fund Iv General Pa...,
  
• Capital Management, L.P.Abr...,
  
• Merilee Raines,
  
• Capital Management, L.P.Abr...,
  
• Rakesh P. Godhani,
  Chief Digital Officer
• Nicholas Corcoran,
  See Remarks
• Stephanie Lovell,
  
• Anil P. Ranganath,
  See remarks